GENVOYA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Genvoya, and what generic alternatives are available?
Genvoya is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.
This drug has five hundred and twenty-six patent family members in fifty-six countries.
The generic ingredient in GENVOYA is cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate profile page.
DrugPatentWatch® Generic Entry Outlook for Genvoya
Genvoya was eligible for patent challenges on November 5, 2019.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 6, 2033. This may change due to patent challenges or generic licensing.
There have been twenty-three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for GENVOYA
International Patents: | 526 |
US Patents: | 10 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 19 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for GENVOYA |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for GENVOYA |
What excipients (inactive ingredients) are in GENVOYA? | GENVOYA excipients list |
DailyMed Link: | GENVOYA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for GENVOYA
Generic Entry Date for GENVOYA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for GENVOYA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
St. Michael's Hospital, Toronto | Phase 2 |
CIHR Canadian HIV Trials Network | Phase 2 |
Unity Health Toronto | Phase 2 |
Pharmacology for GENVOYA
Anatomical Therapeutic Chemical (ATC) Classes for GENVOYA
Paragraph IV (Patent) Challenges for GENVOYA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
GENVOYA | Tablets | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | 150 mg/150 mg/ 200 mg/10 mg | 207561 | 1 | 2023-04-12 |
US Patents and Regulatory Information for GENVOYA
GENVOYA is protected by ten US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of GENVOYA is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting GENVOYA
Use of solid carrier particles to improve the processability of a pharmaceutical agent
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
4-oxoquinoline compound and use thereof as pharmaceutical agent
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Prodrugs of phosphonate nucleotide analogues
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Stable crystal of 4-oxoquinoline compound
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Modulators of pharmacokinetic properties of therapeutics
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Combination therapy
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Tenofovir alafenamide hemifumarate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Stable crystal of 4-oxoquinoline compound
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Tenofovir alafenamide hemifumarate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Modulators of pharmacokinetic properties of therapeutics
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for GENVOYA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for GENVOYA
When does loss-of-exclusivity occur for GENVOYA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
African Regional IP Organization (ARIPO)
Patent: 89
Estimated Expiration: ⤷ Sign Up
Patent: 50
Estimated Expiration: ⤷ Sign Up
Argentina
Patent: 5369
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 09242451
Estimated Expiration: ⤷ Sign Up
Patent: 10210598
Estimated Expiration: ⤷ Sign Up
Patent: 14221210
Estimated Expiration: ⤷ Sign Up
Patent: 15200637
Estimated Expiration: ⤷ Sign Up
Patent: 16250470
Estimated Expiration: ⤷ Sign Up
Patent: 17201473
Estimated Expiration: ⤷ Sign Up
Patent: 18267573
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0911871
Estimated Expiration: ⤷ Sign Up
Patent: 1008664
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 20856
Estimated Expiration: ⤷ Sign Up
Patent: 50521
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 11001885
Estimated Expiration: ⤷ Sign Up
China
Patent: 2123700
Estimated Expiration: ⤷ Sign Up
Patent: 2307573
Estimated Expiration: ⤷ Sign Up
Patent: 3479584
Estimated Expiration: ⤷ Sign Up
Patent: 4940937
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 21225
Estimated Expiration: ⤷ Sign Up
Patent: 00187
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0151009
Estimated Expiration: ⤷ Sign Up
Patent: 0151357
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 16852
Estimated Expiration: ⤷ Sign Up
Patent: 17067
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 96633
Estimated Expiration: ⤷ Sign Up
Patent: 93485
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 10010636
Estimated Expiration: ⤷ Sign Up
Patent: 11011307
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 1313
Estimated Expiration: ⤷ Sign Up
Patent: 2950
Estimated Expiration: ⤷ Sign Up
Patent: 0123
Estimated Expiration: ⤷ Sign Up
Patent: 1071173
Estimated Expiration: ⤷ Sign Up
Patent: 1190125
Estimated Expiration: ⤷ Sign Up
Patent: 1491658
Estimated Expiration: ⤷ Sign Up
Patent: 1591353
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 96633
Estimated Expiration: ⤷ Sign Up
Patent: 93485
Estimated Expiration: ⤷ Sign Up
Patent: 06032
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 53670
Estimated Expiration: ⤷ Sign Up
Patent: 64737
Estimated Expiration: ⤷ Sign Up
Patent: 15679
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 25822
Estimated Expiration: ⤷ Sign Up
Patent: 26380
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 8614
Estimated Expiration: ⤷ Sign Up
Patent: 4227
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 11242
Estimated Expiration: ⤷ Sign Up
Patent: 22213
Estimated Expiration: ⤷ Sign Up
Patent: 11927
Estimated Expiration: ⤷ Sign Up
Patent: 25171
Estimated Expiration: ⤷ Sign Up
Patent: 11522790
Estimated Expiration: ⤷ Sign Up
Patent: 12517432
Estimated Expiration: ⤷ Sign Up
Patent: 14012741
Estimated Expiration: ⤷ Sign Up
Patent: 14221845
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 2377
Estimated Expiration: ⤷ Sign Up
Patent: 10011963
Estimated Expiration: ⤷ Sign Up
Patent: 11008289
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 8978
Estimated Expiration: ⤷ Sign Up
Patent: 4214
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 110994
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 96633
Estimated Expiration: ⤷ Sign Up
Patent: 93485
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 96633
Estimated Expiration: ⤷ Sign Up
Patent: 93485
Estimated Expiration: ⤷ Sign Up
San Marino
Patent: 01500266
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 3544
Estimated Expiration: ⤷ Sign Up
Patent: 0618
Estimated Expiration: ⤷ Sign Up
Patent: 14007744
Estimated Expiration: ⤷ Sign Up
Patent: 201609006W
Estimated Expiration: ⤷ Sign Up
Patent: 201706215U
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 96633
Estimated Expiration: ⤷ Sign Up
Patent: 93485
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1008007
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1645759
Estimated Expiration: ⤷ Sign Up
Patent: 1659971
Estimated Expiration: ⤷ Sign Up
Patent: 1738325
Estimated Expiration: ⤷ Sign Up
Patent: 1784647
Estimated Expiration: ⤷ Sign Up
Patent: 110015581
Estimated Expiration: ⤷ Sign Up
Patent: 110122729
Estimated Expiration: ⤷ Sign Up
Patent: 160093100
Estimated Expiration: ⤷ Sign Up
Patent: 160114728
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 48886
Estimated Expiration: ⤷ Sign Up
Patent: 53897
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 44367
Estimated Expiration: ⤷ Sign Up
Patent: 1040142
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 1193
Estimated Expiration: ⤷ Sign Up
Patent: 3224
Estimated Expiration: ⤷ Sign Up
Uruguay
Patent: 424
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering GENVOYA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 1564210 | COMPOSES 4-OXOQUINOLINIQUES ET LEUR UTILISATION COMME INHIBITEUR DE LA VIH-INTEGRASE (4-OXOQUINOLINE COMPOUNDS AND UTILIZATION THEREOF AS HIV INTEGRASE INHIBITORS) | ⤷ Sign Up |
Cyprus | 1118227 | ⤷ Sign Up | |
Japan | 2007246536 | USE OF 1-(2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)-5-FLUOROCYTOSINE FOR TREATMENT OF HEPATITIS B | ⤷ Sign Up |
Czech Republic | 295074 | (-)-beta-L-2-Hydroxymethyl-5-(5-fluor-1-cytosinyl)-1,3-oxathiolan, farmaceutický prostředek s jeho obsahem a jeho použití ((-)-Beta-L-2-hydroxymethyl-5-(5-fluoro-1-cytosinyl)-1,3-oxathiolate, pharmaceutical preparation containing thereof and its use) | ⤷ Sign Up |
Hungary | E025565 | ⤷ Sign Up | |
Canada | 2470365 | COMPOSES 4-OXOQUINOLINIQUES ET LEUR UTILISATION COMME INHIBITEUR DE LA VIH-INTEGRASE (4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for GENVOYA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2487163 | PA2016039 | Lithuania | ⤷ Sign Up | PRODUCT NAME: ATAZANAVIRAS + KOBICISTATAS; REGISTRATION NO/DATE: EU/1/15/1025 20150713 |
1564210 | C01564210/01 | Switzerland | ⤷ Sign Up | CHANGE OF ADDRESS OF THE OWNER: JAPAN TOBACCO INC., 1-1, TORANOMON 4-CHOME, MINATO-KU, TOKYO 105-6927, JP |
2487162 | 61/2016 | Austria | ⤷ Sign Up | PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON UND DARUNAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON, INSVBESONDERE DARUNAVIR-ETHANOLAT; REGISTRATION NO/DATE: EU/1/14/967 (MITTEILUNG) 20141121 |
1564210 | CA 2013 00058 | Denmark | ⤷ Sign Up | PRODUCT NAME: ELVITEGRAVIR I ENHVER FORM SOM ER OMFATTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/13/830/001-002 20130524 |
1564210 | 92307 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: ELVITEGRAVIR SOUS TOUTES SES FORMES COMME PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/13/830/001-002 - STRIBILD-ELVITEGRAVIR/... 20130527 |
2049506 | 15C0078 | France | ⤷ Sign Up | PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE COBICISTAT; REGISTRATION NO/DATE: EU/1/13/830/001-002 20130527 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |